PEDIATRIC ONCOLOGY PROGRAM

儿科肿瘤学项目

基本信息

  • 批准号:
    6589984
  • 负责人:
  • 金额:
    $ 25.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2002
  • 资助国家:
    美国
  • 起止时间:
    2002-05-06 至 2003-01-31
  • 项目状态:
    已结题

项目摘要

Description: (Applicant's Description) The Pediatric Oncology Program is comprised of clinical oncologists, surgeons, pathologists, and basic scientists whose interests are related to the diseases of pediatric cancer patients. The overall goal of the Pediatric Oncology Program is to reduce the cancer burden in the pediatric population by its research, education, and clinical programs. To accomplish this goal, the Program has established an integrated group of members, organized in four focus areas: 1) clinical investigations, 2) a clinical and research bone marrow transplant (BMT) program, 3) clinical translational research in leukemias, cytogenetics, and brain tumors, 4) basic science research in DNA tumor viruses, lymphocyte signal transduction, and fusion protein transcription factors created by chromosomal translocations in childhood ALL. The clinical program is an active participant in the Children?s Cancer Group (CCG), and utilizes investigator-initiated protocols developed by Cancer Center members and by the cooperative group whenever possible. Each year approximately 150 new oncology patients are evaluated and/or treated by the oncology staff, and an additional 25-35 children are transplanted on various protocols in the pediatric BMT unit. Protocol development over the past year has included 13 investigator-initiated and 49 CCG protocols, with 153 patients enrolled. Program members are highly interactive with respect to clinical protocol development, translational research, and basic research, as evidenced by the fact that 36% of the 132 publications have intra-or inter-program collaborations despite the fact that most members are new. Future plans will build upon this foundation of interaction in specific areas including: 1)continue integration of Pediatric and Adult programs in Neuro-oncology and BMT; 2)development of a Cancer Genetics Clinic to serve as a focus for new translational and basic research; 3)establishment of a clinical and basic research interest group for studying EBV-related lymphoproliferative disease; 4)increased research in cancer survivorship; and 5)faculty career development for new translational and basic scientists interested in areas related to Pediatric Oncology. This is one of a few approved Pediatric Oncology programs within NCI designated Comprehensive Cancer Centers whose growth has been supported by the UCCC and whose growth is projected to continue in the next five years.
描述:(申请者描述)儿科肿瘤学专业是 由临床肿瘤学家、外科医生、病理学家和基础 对儿童癌症疾病感兴趣的科学家 病人。儿科肿瘤学计划的总体目标是减少 儿科人群的癌症负担由其研究、教育和 临床项目。为了实现这一目标,该方案建立了一个 整合的成员小组,按四个重点领域组织:1)临床 调查,2)临床和研究骨髓移植(BMT) 方案,3)白血病的临床翻译研究,细胞遗传学,和 脑肿瘤,4)DNA肿瘤病毒,淋巴细胞的基础科学研究 信号转导和融合蛋白转录因子 儿童ALL的染色体易位。临床方案是一项积极的 儿童-S癌症小组的参与者,并利用 由研究人员发起的由癌症中心成员和 只要有可能,就组成合作小组。每年大约有150个新的肿瘤科 由肿瘤科工作人员对患者进行评估和/或治疗,并另外 在儿科BMT中,25-35名儿童通过不同的方案进行移植 单位。 在过去的一年里,礼仪的制定包括13名调查人员发起的 CCG方案49例,入选患者153例。计划成员高度重视 关于临床方案开发的互动、翻译 研究和基础研究,这一事实证明了132人中的36% 出版物有计划内或计划间的合作,尽管事实是 大多数成员都是新成员。未来的计划将建立在这一基础上 具体领域的互动包括:1)继续整合儿科 和成人神经肿瘤学和骨髓移植计划;2)癌症的发展 遗传学诊所将成为新的翻译和基础研究的重点; 3)建立临床和基础研究学习兴趣小组 EB病毒相关淋巴增生性疾病;4)增加癌症研究 生存能力;5)新的翻译和基础专业的教师职业发展 对儿科肿瘤学相关领域感兴趣的科学家。这是一个 NCI指定的综合性儿科肿瘤学项目寥寥无几 由UCCC支持的癌症中心,其增长是 预计在未来五年内将继续下去。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert L Garcea其他文献

Robert L Garcea的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert L Garcea', 18)}}的其他基金

Transcriptional Responses Induced by Polyomavirus Attachment and Entry
多瘤病毒附着和进入诱导的转录反应
  • 批准号:
    8960338
  • 财政年份:
    2014
  • 资助金额:
    $ 25.04万
  • 项目类别:
L1 capsomeres as a next generation preventive HPV vaccine
L1 壳粒作为下一代预防性 HPV 疫苗
  • 批准号:
    8729810
  • 财政年份:
    2013
  • 资助金额:
    $ 25.04万
  • 项目类别:
POLYOMA VIRUS REPLICATION
多瘤病毒复制
  • 批准号:
    8362556
  • 财政年份:
    2011
  • 资助金额:
    $ 25.04万
  • 项目类别:
GROWING AND FREEZING CELLS IN 3-D MATRICES
在 3D 基质中培养和冷冻细胞
  • 批准号:
    8362555
  • 财政年份:
    2011
  • 资助金额:
    $ 25.04万
  • 项目类别:
THE ENDOCYTIC PATHWAY OF BOVINE PAPILLOMAVIRUS USING EM TOMOGRAPHY
使用电子断层扫描技术研究牛乳头状病毒的内吞途径
  • 批准号:
    8362537
  • 财政年份:
    2011
  • 资助金额:
    $ 25.04万
  • 项目类别:
THE ENDOCYTIC PATHWAY OF BOVINE PAPILLOMAVIRUS USING EM TOMOGRAPHY
使用电子断层扫描技术研究牛乳头状病毒的内吞途径
  • 批准号:
    8170834
  • 财政年份:
    2010
  • 资助金额:
    $ 25.04万
  • 项目类别:
THE ENDOCYTIC PATHWAY OF BOVINE PAPILLOMAVIRUS USING EM TOMOGRAPHY
使用电子断层扫描技术研究牛乳头状病毒的内吞途径
  • 批准号:
    7955053
  • 财政年份:
    2009
  • 资助金额:
    $ 25.04万
  • 项目类别:
Ll capsomeres as a next generation preventive HPV vaccine
Ll 壳粒作为下一代预防性 HPV 疫苗
  • 批准号:
    7727548
  • 财政年份:
    2009
  • 资助金额:
    $ 25.04万
  • 项目类别:
THE ENDOCYTIC PATHWAY OF BOVINE PAPILLOMAVIRUS USING EM TOMOGRAPHY
使用电子断层扫描技术研究牛乳头状病毒的内吞途径
  • 批准号:
    7722846
  • 财政年份:
    2008
  • 资助金额:
    $ 25.04万
  • 项目类别:
PEDIATRIC ONCOLOGY PROGRAM
儿科肿瘤学项目
  • 批准号:
    6664439
  • 财政年份:
    2002
  • 资助金额:
    $ 25.04万
  • 项目类别:

相似海外基金

Project 4 - Controlling the Latent-to-Lytic Switch in Epstein-Barr Virus
项目 4 - 控制 Epstein-Barr 病毒中的潜伏至裂解转换
  • 批准号:
    10910338
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
Epstein-Barr Virus nuclear antigen leader protein in transcription regulation
Epstein-Barr病毒核抗原前导蛋白在转录调控中的作用
  • 批准号:
    10829620
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
Exploiting Metabolism to Uncloak Epstein-Barr Virus Immunogens in Latently Infected B-cells
利用代谢揭示潜伏感染 B 细胞中的 Epstein-Barr 病毒免疫原
  • 批准号:
    10889325
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
Understanding the immune response changes to clinical interventions for Epstein-Barr virus infection prior to lymphoma development in children after organ transplants (UNEARTH)
了解器官移植后儿童淋巴瘤发展之前针对 Epstein-Barr 病毒感染的临床干预的免疫反应变化(UNEARTH)
  • 批准号:
    10755205
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
Regulation and Functions of the Epstein-Barr Virus Lytic Switch Protein
EB 病毒裂解开关蛋白的调控和功能
  • 批准号:
    489085
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
    Operating Grants
Characterization of Epstein-Barr Virus Subversion of the Host SMC5/6 Restriction Pathway
Epstein-Barr 病毒颠覆宿主 SMC5/6 限制途径的特征
  • 批准号:
    10679118
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
Epstein Barr Virus Driven Mechanisms of Post Transplant Lymphoproliferative Disease
EB 病毒驱动的移植后淋巴增殖性疾病的机制
  • 批准号:
    10755055
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
Deciphering the Role of Epstein-Barr Virus Molecular Mimicry and B cell Transformation in Multiple Sclerosis
解读 Epstein-Barr 病毒分子拟态和 B 细胞转化在多发性硬化症中的作用
  • 批准号:
    10568864
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
Project 2: Novel investigation of Epstein-Barr virus as a potential cause of conjunctival squamous cell carcinoma among people living with HIV in Zimbabwe
项目 2:对 Epstein-Barr 病毒作为津巴布韦艾滋病毒感染者结膜鳞状细胞癌潜在原因的新调查
  • 批准号:
    10598376
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
Project 3 - Characterizing the Amplification Factories of Epstein-Barr Virus and Kaposi's Sarcoma-associated Herpesvirus
项目 3 - 描述 Epstein-Barr 病毒和卡波西肉瘤相关疱疹病毒的扩增工厂
  • 批准号:
    10910337
  • 财政年份:
    2023
  • 资助金额:
    $ 25.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了